Latest News for: ros1

Edit

ROZLYTREK's Market Growth Reflects Transforming Treatment For NTRK And ROS1-Positive Cancers Delveinsight

MENA FN 12 Mar 2025
(MENAFN - PR Newswire) As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from ... .
Edit

ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight

PR Newswire 12 Mar 2025
It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary active metabolite, M5, exhibits similar inhibitory activity against TRK, ROS1, and ALK.
  • 1
×